---

Lymphadenitis — Comprehensive Overview

---

1. Definition

• Acute — rapid onset, usually bacterial or viral; nodes are tender and swollen
• Chronic — persistent or recurrent; often associated with mycobacterial infection, fungi, parasites, or autoimmune disease
• Nonspecific reactive — stereotypical response to local or systemic antigenic stimulation
• Specific/granulomatous — characteristic morphologic patterns (e.g., TB, cat-scratch disease, sarcoidosis)

Robbins, Cotran & Kumar Pathologic Basis of Disease — Lymph nodes are activated by antigenic stimulation, producing morphologic changes; "trivial injuries and infections induce subtle changes, while more significant infections inevitably produce nodal enlargement and sometimes leave residual scarring."

---

2. Epidemiology

• Acute bacterial lymphadenitis is common in all age groups; cervical lymphadenitis is especially prevalent in children and adolescents following upper respiratory tract infections.
• Tuberculous lymphadenitis (scrofula) is the most common form of extrapulmonary TB globally; it more commonly affects young women and children. In the United States, it is more often caused by non-tuberculous mycobacteria (NTM) than M. tuberculosis.
• Filarial lymphadenitis (Wuchereria bancrofti, Brugia spp.) is the leading cause of lymphadenitis in tropical endemic areas; episodic lymphadenitis most commonly affects adolescents.
• Mesenteric lymphadenitis is a common cause of acute abdominal pain in children, often mimicking appendicitis.
• Lymphadenitis is seen across all geographic regions; in developing countries, TB and filariasis dominate; in developed countries, bacterial and viral (EBV, CMV) causes are most common.
• Patients co-infected with HIV frequently develop generalized lymphadenitis.

ROSEN's Emergency Medicine; Goldman-Cecil Medicine; Bailey and Love's Surgery

---

3. Etiology

Bacterial

Viral

• Epstein-Barr virus (EBV) — infectious mononucleosis (extensive cervical lymphadenitis)
• Cytomegalovirus (CMV)
• HIV — generalized lymphadenopathy
• Other systemic viral infections (especially in children)

Parasitic / Fungal

• Wuchereria bancrofti, Brugia malayi — filarial lymphadenitis
• Toxoplasma gondii — toxoplasmic lymphadenitis
• Histoplasma capsulatum, Cryptococcus — in immunocompromised patients

Other

• Sarcoidosis — noncaseating granulomatous lymphadenitis
• Kikuchi-Fujimoto disease — histiocytic necrotizing lymphadenitis
• Reactive/nonspecific — following any local or systemic inflammation

Bailey and Love's Surgery; Harriet Lane Handbook; Textbook of Family Medicine

---

4. Risk Factors

• Age: Children and young adults are disproportionately affected
• Immunosuppression: HIV/AIDS, organ transplantation, chemotherapy — predispose to atypical and opportunistic infections
• Geographic exposure: Residence in or travel to TB-endemic or filarial-endemic regions
• Animal exposure: Cat contact (Bartonella), livestock (Brucella)
• Poor dental hygiene: Dental abscesses → cervical lymphadenitis
• Recurrent tonsillitis/pharyngitis: Persistent drainage to cervical nodes
• Skin breaks/wounds: Portal of entry for bacteria (axillary, inguinal lymphadenitis following limb infections)
• Malnutrition: Impaired immune response
• Occupational exposure: Healthcare workers, farmers (TB, Brucella)
• Intravenous drug use: Bloodstream bacteremia → generalized lymphadenitis

---

5. Pathophysiology

1. Antigenic stimulation: Microorganisms or their products are transported via afferent lymphatics to regional lymph nodes.
2. Immune activation: Resident macrophages and dendritic cells present antigens to lymphocytes. Within days, primary follicles enlarge and develop pale-staining germinal centers (secondary follicles) — sites of B-cell proliferation and antibody affinity maturation.
3. Follicular hyperplasia: Germinal centers show a dark zone (proliferating centroblasts) and light zone (centrocytes), with interspersed macrophages (tangible-body macrophages) clearing apoptotic cells. Paracortical T-cell zones may also expand.
4. Neutrophil infiltration (pyogenic bacteria): When pyogenic organisms (e.g., S. aureus) are causative, neutrophils infiltrate follicles → follicular necrosis → liquefaction → abscess formation (entire node may convert to pus).
5. Sinus histiocytosis: Endothelial cells lining sinuses become activated and enlarge.
6. Abscess/sinus tract formation: Suppurative infection may penetrate the nodal capsule, track to overlying skin → draining sinuses. Healing leaves fibrous scarring.

Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 551–552

---

6. Clinical Features & Diagnosis

History & Physical Examination

• Acute lymphadenitis: Tender, enlarged, warm, erythematous nodes; constitutional symptoms (fever, malaise, anorexia); may become fluctuant (abscess)
• Chronic lymphadenitis: Painless, rubbery, or matted nodes; may have sinus tracts (TB); bilateral vs. unilateral patterns help narrow etiology
• Identify the primary focus: tonsillitis (cervical), skin infection (axillary/inguinal), dental abscess (submandibular), bowel inflammation (mesenteric)

Investigations

Harriet Lane Handbook; ROSEN's Emergency Medicine; Textbook of Family Medicine

---

7. Complications

Goldman-Cecil Medicine; Robbins Pathologic Basis of Disease; Goldman-Cecil Medicine (Filariasis chapter)

---

8. Non-Pharmacological Therapy

1. Treat the primary source of infection: Lymphadenitis resolves when the underlying cause (tonsillitis, dental abscess, skin wound) is addressed. This is the cornerstone of initial management.
2. Warm compresses: Applied to swollen, tender nodes to promote comfort and local circulation; may facilitate spontaneous drainage.
3. Rest and adequate hydration: Supportive care, especially in febrile illness.
4. Incision and drainage (I&D): Indicated for fluctuant abscess that has failed to respond to antibiotics or requires expedited decompression. Exceptions:
   • TB lymphadenitis: I&D is contraindicated — causes permanent sinuses and prolonged drainage; surgical excision is preferred if medical therapy fails.
   • NTM (atypical mycobacteria): I&D is contraindicated — causes chronic fistulization; excisional biopsy is curative management.
5. Surgical excision:
   • NTM lymphadenitis: Curative first-line procedure
   • TB lymphadenitis: Reserved for failed medical therapy or unclear diagnosis
   • Persistent nodes (4–6 weeks) not responding to antibiotics: Refer for excisional biopsy to rule out malignancy
6. Needle aspiration (FNA): For diagnostic purposes (culture, cytology) and symptomatic relief in cat-scratch disease (self-limited; resolves 2–4 months)
7. Observation: Self-limited causes (cat-scratch disease, viral lymphadenitis) — watchful waiting is appropriate; no intervention needed unless complicated
8. Dietary and lifestyle measures: Reduce immunosuppressive risk factors (nutrition, smoking cessation, glucose control in diabetes)

---

9. Pharmacological Therapy

Empirical Antibiotic Therapy (Bacterial Lymphadenitis)

Specific/Organism-Directed Therapy

Analgesics / Anti-inflammatory

• NSAIDs (ibuprofen, naproxen): Reduce pain and fever in mild-to-moderate disease
• Paracetamol (acetaminophen): Antipyretic and analgesic, especially in children

Harriet Lane Handbook; Textbook of Family Medicine 9e; ROSEN's Emergency Medicine; Goldman-Cecil Medicine

---

Summary Table

---

• Robbins, Cotran & Kumar Pathologic Basis of Disease (pp. 551–552)
• ROSEN's Emergency Medicine: Concepts and Clinical Practice
• Goldman-Cecil Medicine, International Edition
• Bailey and Love's Short Practice of Surgery, 28th Ed.
• Textbook of Family Medicine, 9th Ed.
• Harriet Lane Handbook, 23rd Ed.

---

Anti-SmD1 (Anti-Sm D1 Antibody) - Complete Clinical Guide

---

What is SmD1?

Molecular Structure of the Sm Antigen

• B/B' (27/28 kDa)
• D1, D2, D3 (~14 kDa each)
• E, F, G (smaller)

Tietz Textbook of Laboratory Medicine, 7th Ed.

---

What Makes SmD1 the Most Specific Sm Epitope?

A glycine-arginine-glycine (Gly-Arg-Gly) motif containing symmetrical dimethylarginine residues on the D1, D2, D3, and B/B' proteins.

Tietz Textbook of Laboratory Medicine, 7th Ed., pp. 3295-3297

---

Clinical Significance

1. Diagnostic Marker for SLE

"A positive anti-ds-DNA or anti-Sm essentially rules in SLE."

"Antibodies to double-stranded DNA and the Smith (Sm) antigen are virtually diagnostic [of SLE]."

2. Association with Specific Clinical Manifestations

Henry's Clinical Diagnosis and Management by Laboratory Methods

3. Differentiation from Anti-U1-RNP

---

Anti-SmD1 vs. Broad Anti-Sm Assays

Tietz Textbook of Laboratory Medicine, 7th Ed.

---

How Anti-Sm Antibodies are Pathogenic

1. Immune complex formation - Anti-SmD1/anti-snRNP antibodies form immune complexes that deposit in tissues (especially glomeruli in lupus nephritis), activating complement and triggering inflammation.
2. Nucleosome/snRNP release - Apoptotic cells release Sm antigens from the nucleus; in SLE, defective clearance allows these antigens to stimulate autoantibody production.
3. Toll-like receptor activation - snRNA components of Sm particles activate TLR7/TLR8 on dendritic cells, amplifying the autoimmune response.
4. Direct tissue injury - Anti-Sm antibodies may cross-react with cell-surface or intracellular proteins in target organs (especially brain tissue in NPSLE).

Robbins, Cotran & Kumar Pathologic Basis of Disease; Comprehensive Clinical Nephrology, 7th Ed.

---

Detection Methods

1. ELISA (Enzyme-Linked Immunosorbent Assay) - Most widely used; can use SmD1 peptide specifically
2. Line immunoassay (LIA) / dot blot - Simultaneous detection of multiple ENA antibodies
3. Addressable laser bead immunoassay (ALBIA/Luminex) - High-throughput multiplex; can detect SmD1 specifically
4. Immunodiffusion (Ouchterlony) - Historical gold standard; detects whole Sm antigen; less sensitive for low-titer antibodies
5. Counterimmunoelectrophoresis - Historical; less commonly used now

• The specific antigen used (SmD1 peptide vs. whole Sm complex vs. B/B' peptide)
• The detection method (ELISA vs. immunodiffusion)
• The patient's ethnicity
• Whether the patient is in an active or quiescent phase (anti-Sm levels can fluctuate over time)

---

Summary: Key Points on Anti-SmD1 Positivity

---

• Tietz Textbook of Laboratory Medicine, 7th Ed. (pp. 3292-3297)
• Henry's Clinical Diagnosis and Management by Laboratory Methods (Antibodies to Sm and Nuclear Ribonucleoprotein section)
• Robbins, Cotran & Kumar Pathologic Basis of Disease (Table 6.10)
• Robbins & Kumar Basic Pathology (Spectrum of Autoantibodies in SLE)
• Symptom to Diagnosis: An Evidence-Based Guide, 4th Ed.
• Comprehensive Clinical Nephrology, 7th Ed.

---

Serologic Profile Interpretation

The Panel at a Glance

---

Interpretation: What This Profile Means

1. Diagnosis: SLE With Overlap Features

"Anti-Smith (anti-Sm) antibodies are the most common anti-RBP, present in ~30% of patients, and are highly specific for SLE (55–100%). Given their high specificity, both anti-dsDNA and anti-Sm antibodies are the only ANA subtypes included in the current EULAR/ACR criteria."

---

2. Anti-SmD1 +++ — What Strong Positivity Signals

• Highly specific for SLE — a strong positive essentially rules in the diagnosis
• Associated with lupus nephritis (renal immune complex deposition)
• Associated with neuropsychiatric SLE (NPSLE) — cognitive dysfunction, seizures, psychosis
• Anti-Sm and anti-U1-RNP are "linked" antibodies — they frequently co-occur (a phenomenon called linkage); the co-positivity here is typical
• Strong SmD1 positivity reflects active autoimmune drive against the spliceosomal snRNP complex

Goldman-Cecil Medicine: "Anti-Sm and anti-RNP antibodies are related antibodies that commonly occur together in SLE, a phenomenon called linkage."

---

3. Anti-SS-A/Ro60 ++ AND Anti-SS-A/Ro52 ++ — Distinct and Additive Risks

Anti-Ro60 (classic SS-A):

• Associated with subacute cutaneous lupus erythematosus (SCLE) — annular or papulosquamous photosensitive rash
• Associated with ANA-negative SLE (Ro antibodies can be the only positive in ~5% of SLE)
• Associated with lupus nephritis, vasculitis, lymphadenopathy, photosensitivity, leukopenia
• Neonatal lupus and congenital heart block (CHB) — critically important if patient is female of childbearing age
• Associated with sicca syndrome (dry eyes, dry mouth)
• Associated with complement deficiency states (homozygous C2/C4 deficiency)

Anti-Ro52 (TRIM21) — Separate Significance:

• Must be tested separately from Ro60 (up to 20% of sera show masked reactivities when both antigens are in the same ELISA well)
• Anti-Ro52 alone (without Ro60) is seen in scleroderma and myositis overlap
• Anti-Ro52 + anti-Ro60 together: seen in primary Sjögren syndrome and SLE with systemic features
• Anti-Ro52 is frequently co-detected with myositis-specific antibodies (e.g., anti-Jo-1) and is a myositis-associated antibody (MAA)
• In the context of this panel: the Ro52 positivity may represent an additional overlap with inflammatory myopathy or scleroderma spectrum

Henry's Clinical Diagnosis and Management by Laboratory Methods: "Different clinical associations for each system... anti-Ro52/TRIM21 alone is also associated with scleroderma and myositis."

---

4. Anti-U1-snRNP ++ — Overlap and Pulmonary Risk

• Anti-U1-RNP (U1-snRNP) in isolation at high titer is diagnostic for Mixed Connective Tissue Disease (MCTD)
• Here it co-occurs with anti-Sm — in this context it does not define MCTD as a standalone diagnosis; instead it signals an SLE-dominant overlap syndrome
• However, anti-RNP raises specific clinical risks:
  • Pulmonary arterial hypertension (PAH) — a serious, potentially life-threatening complication
  • Raynaud's phenomenon
  • Musculoskeletal involvement (arthritis, myositis, puffy fingers)
  • Esophageal dysmotility
  • Elevated type I interferon gene signature — contributes to disease severity

"Anti-RNP: Not SLE-specific. Associated with overlap syndromes and increased risk for pulmonary hypertension. Correlates with high interferon gene signature."

Goldman-Cecil Medicine: "In the absence of anti-Sm, anti-RNP antibodies may characterize patients with overlap syndromes, including a specific entity termed mixed connective tissue disease."

---

Consolidated Clinical Risk Map

---

Special Situations Requiring Immediate Action

If Patient is Female and Pregnant (or Planning Pregnancy):

1. Neonatal lupus — transient cutaneous rash, thrombocytopenia, liver abnormalities in the neonate
2. Congenital heart block (CHB) — potentially permanent, life-threatening fetal 2nd-3rd degree AV block

• Refer to high-risk obstetrics
• Fetal echocardiography starting at 16-18 weeks gestation, every 1-2 weeks until 26 weeks (peak risk window)
• Hydroxychloroquine (HCQ) during pregnancy significantly reduces CHB risk in women with prior affected fetus
• If 1st or 2nd degree CHB detected on fetal echo: fluorinated steroids (dexamethasone) may be considered

Harrison's Principles of Internal Medicine: "The presence of Ro antibodies, particularly in high titer, should prompt referral to high-risk obstetricians who can perform fetal echocardiography... HCQ in pregnancy significantly reduces the risk of congenital heart block."

---

Summary Diagnosis

---

Recommended Next Steps

1. Complete SLE workup: anti-dsDNA, C3, C4, CBC with differential, urinalysis + UPCR, eGFR, LFTs
2. Antiphospholipid antibodies: anticardiolipin IgG/IgM, anti-β2GP-I, lupus anticoagulant (~50% of SLE patients co-positive)
3. Renal assessment: 24-hour urine protein or UPCR to screen for lupus nephritis
4. Pulmonary: Echocardiogram (PAH screen given U1-snRNP), HRCT chest if respiratory symptoms (ILD)
5. Sicca workup: Schirmer's test, unstimulated salivary flow, lip biopsy if Sjögren overlap suspected
6. Muscle enzymes: CK, aldolase, LDH (Ro52 + U1-snRNP overlap = myositis screen)
7. Pregnancy counseling if applicable (anti-Ro60 ++ mandates fetal cardiac surveillance)
8. Complement levels (C3, C4): Low complement supports active immune complex disease / nephritis activity

---

• Harrison's Principles of Internal Medicine, 22nd Ed. — Table 366-2 (Autoantibodies in SLE), Neonatal Lupus section
• Goldman-Cecil Medicine, International Ed. — Other Antinuclear Antibodies, Table 237-1
• Henry's Clinical Diagnosis and Management by Laboratory Methods — Antibodies to SS-A/Ro and SS-B/La; Clinical Subsets of SLE
• Tietz Textbook of Laboratory Medicine, 7th Ed. — Anti-Sm, Anti-Ro sections
• Robbins, Cotran & Kumar Pathologic Basis of Disease

---

Valvular Heart Disease: Moderate MR / AR / AS — Degenerative Etiology

---

Overview: Why This Combination Matters

• Each lesion individually at moderate stage is below surgical intervention thresholds — but together they compound hemodynamic load on the left ventricle
• The degenerative etiology is the same underlying mechanism: progressive fibrocalcific degeneration driven by aging, inflammation, and atherosclerotic risk factors
• Moderate disease is the critical surveillance window — the stage where close monitoring and risk factor control can delay or prevent progression to severe disease requiring intervention

---

1. Degenerative Etiology — Shared Pathophysiology

The degenerative process involves proliferative and inflammatory changes with lipid accumulation, infiltration of macrophages and T lymphocytes, followed by fibrosis and calcification. Risk factors are identical to those for atherosclerosis: elevated LDL, diabetes, hypertension, and smoking. — Mulholland and Greenfield's Surgery, 7th Ed.

---

2. Classification of Moderate Severity (Echocardiographic Criteria)

Aortic Stenosis — Moderate

Aortic Regurgitation — Moderate

• Moderate AR: regurgitant volume >30 but <60 mL/beat; EROA >10 but <30 mm²
• Vena contracta width: 3–6 mm
• Holodiastolic flow reversal: partial (descending aorta)
• AR fraction: 30–50%

Mitral Regurgitation — Moderate

• Vena contracta width: 3–6.9 mm
• EROA (PISA): 0.20–0.39 cm²
• Regurgitant volume: 30–59 mL/beat
• Regurgitant fraction: 30–49%
• LA and LV size: mildly enlarged

---

3. Pathophysiology of Each Lesion

Aortic Stenosis (AS) — Pressure Overload

1. Fixed outflow obstruction → increased LV systolic pressure (pressure overload)
2. Compensatory LV hypertrophy (concentric) → increased wall thickness
3. Stiff, non-compliant ventricle → diastolic dysfunction (impaired relaxation and filling)
4. Increased myocardial O₂ demand (hypertrophy + elevated wall tension + prolonged ejection time) + decreased perfusion → subendocardial ischemia → fibrosis
5. Symptoms emerge in sequence: angina → syncope → heart failure (mean survival 5, 3, 2 years respectively once each symptom appears)
6. Moderate AS: ~0.1 cm² reduction in valve area per year — progression to severe is eventual in most patients

Aortic Regurgitation (AR) — Volume Overload

1. Regurgitant jet during diastole → LV receives both normal preload + regurgitant volume → LV volume overload
2. Eccentric LV hypertrophy (dilation + wall thickening) — LV adapts via Frank-Starling mechanism
3. Increased preload sustains stroke volume; effective forward flow maintained in early chronic AR
4. Over time: LV becomes progressively dilated → systolic dysfunction
5. Reduced diastolic aortic pressure + elevated LV diastolic pressure → wide pulse pressure → bounding peripheral pulses (Corrigan's, de Musset's, Quincke's signs)
6. In moderate AR: asymptomatic for many years; 10-year survival 94% (mild) vs. 69% (severe)

Mitral Regurgitation (MR) — Volume Overload + Left Atrial Pressure

1. Systolic regurgitation into LA → LA volume and pressure overload
2. LV compensates with eccentric hypertrophy (volume overload state)
3. Increased LA pressure → pulmonary venous hypertension → dyspnea
4. Chronic LA dilation → atrial fibrillation (MR's most common complication)
5. In degenerative MR (myxomatous/prolapse): leaflet billowing into LA during systole → regurgitant jet
6. Mitral annular calcification (MAC) — a degenerative variant; causes restriction ± regurgitation; associated with systemic atherosclerosis and poor cardiovascular prognosis

---

4. Clinical Presentation

Symptoms (typically appear late, overlap between lesions)

Physical Examination Findings

---

5. Diagnosis

Echocardiography (Gold Standard for All Three)

• TTE (transthoracic echo) is first-line: assesses valve morphology, severity by Doppler, LV size and function (EF, dimensions), LA size, pulmonary artery pressure
• TEE: if TTE is inconclusive; detailed mitral valve anatomy for repair planning
• 3D echocardiography: PISA and vena contracta measurement for MR; optimal for surgical/transcatheter planning
• Dobutamine stress echo: if moderate AS with low EF (to distinguish true severe AS from pseudo-severe AS in low-flow/low-gradient states)

Cardiac MRI (CMR)

• Definitive measurement of regurgitant fraction and volumes in AR and MR
• Useful when echo is inconclusive or discordant with clinical findings
• Assessment of aortic root dimensions in AR
• LV fibrosis quantification (late gadolinium enhancement)

ECG

• AS: LV hypertrophy pattern (Sokolow-Lyon criteria); ST-T changes
• AR: LV hypertrophy + dilation pattern; prolonged QRS
• MR: LA enlargement (P-mitrale, P >120 ms, bifid); AF; LV hypertrophy

Chest X-Ray

• AS: LV hypertrophy (rounded apex), aortic valve calcification, post-stenotic aortic dilation
• AR: cardiomegaly (LV dilation), aortic root dilation
• MR: cardiomegaly, LA enlargement (double density sign, elevation of left main bronchus), pulmonary vascular congestion

Exercise Stress Testing

• Useful in moderate AS: to unmask symptoms in ostensibly asymptomatic patients; should be supervised by a cardiologist
• Contraindicated in symptomatic severe valvular disease

Cardiac Catheterization

• Reserved for preoperative coronary artery disease assessment in patients >40 years or with risk factors
• No longer used for routine AS/AR/MR severity assessment (replaced by echo)

---

6. Management of Moderate Degenerative Multi-Valve Disease

General Principles

1. Moderate severity = below guideline thresholds for surgical intervention for any individual lesion
2. However, multi-valve moderate disease compounds hemodynamic stress — lower threshold for referral and closer surveillance is warranted
3. All three lesions share the same risk factor profile as atherosclerosis — aggressive risk factor control is the cornerstone of non-pharmacological management

---

Non-Pharmacological Therapy

"Patients with mild to moderate AR and those with severe AR with a normal LVEF and only mild ventricular dilation may engage in aerobic forms of exercise. However, patients with AR who have limitations of cardiac reserve and/or evidence of declining LV function should not engage in competitive sports or strenuous activities."

---

Pharmacological Therapy

A. Aortic Stenosis (Moderate)

B. Aortic Regurgitation (Moderate)

C. Mitral Regurgitation (Moderate)

"Pregnancy in patients with mild or moderate mitral regurgitation can be managed very safely with a conservative regimen of reduced physical activity, salt restriction, and low doses of a diuretic."

---

Surveillance Schedule (Echocardiographic Monitoring)

---

Intervention Thresholds (When Moderate Becomes an Indication)

"AVR is also indicated in patients with moderate AS requiring cardiac surgery for other indications." — This is particularly relevant here: if MR surgery becomes necessary, concurrent AVR for moderate AS should be performed at the same operative sitting.

---

7. Special Considerations in Multi-Valve Disease

1. Compounded LV burden: Moderate MR (volume overload) + moderate AS (pressure overload) + moderate AR (volume overload) = triple hemodynamic challenge on the LV. The LV EF may remain falsely preserved (EF normal despite impaired contractility) due to MR/AR offloading the ventricle. A falling EF even within normal range (e.g., 60% → 55%) is a red flag.
2. Cascade of AF: Left atrial dilation (from MR/AR) predisposes to AF. AF, in turn, worsens MR (annular dilation with rate-related changes) and poorly tolerated in AS (loss of atrial contribution to filling of hypertrophied LV). Atrial fibrillation in this multi-valve context should prompt urgent cardiology review.
3. Coronary disease co-assessment: Degenerative valvular disease shares risk factors with CAD. Coronary angiography is needed preoperatively (>40 years or risk factors). Concurrent CAD further reduces the ischemic threshold in AS.
4. TAVR/TAVI consideration: For high-surgical-risk elderly patients who progress to severe AS, TAVR is increasingly preferred. Mild-moderate AR after TAVR (30–50%) is a known complication to monitor.
5. Endocarditis risk: While prophylaxis is not routinely recommended for native degenerative valvular disease (AHA 2007/2021 guidelines), any dental or invasive procedure should be preceded by good oral hygiene maintenance. The presence of multiple diseased valves means endocarditis would be catastrophic.

---

8. Summary Management Algorithm

Moderate MR + Moderate AR + Moderate AS (Degenerative)
                        │
         ┌──────────────┼──────────────┐
    Asymptomatic     Early symptoms    Significant symptoms
    Normal LV EF     (mild dyspnea)    (NYHA II-III / syncope)
         │                 │                    │
   Serial echo         Optimize meds +     Cardiology referral
   q 12-24 months      echo q 6-12m        Stress test / CMR
         │                 │                    │
   Risk factor         Re-assess for        Consider if any
   control             progression to       lesion now severe
   (BP, lipids,        severe disease       → Surgical/TAVR
   DM, smoking)                              planning

---

Sources

• Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set (Chapters 73, 76, 77)
• Mulholland and Greenfield's Surgery: Scientific Principles and Practice, 7th Ed. (Chapter 82 — Degenerative Calcific Aortic Stenosis)
• Textbook of Clinical Echocardiography (MR/AR quantitation sections)
• Symptom to Diagnosis: An Evidence-Based Guide, 4th Ed. (Aortic Regurgitation treatment summary)
• Creasy & Resnik's Maternal-Fetal Medicine (Moderate MR in pregnancy)
• Harrison's Principles of Internal Medicine, 22nd Ed.

---

Definitions: Valvular Heart Disease (Moderate MR / AR / AS) — Degenerative Etiology

---

1. Valvular Heart Disease (VHD) — General Definition

• Stenosis — pathological narrowing of a valve orifice, obstructing forward flow
• Regurgitation (insufficiency/incompetence) — failure of a valve to close completely, allowing backward (retrograde) flow
• Or both (mixed lesion)

---

2. Degenerative Valve Disease — Definition

"Degenerative valve disease is a term used to describe changes that affect the integrity of valvular extracellular matrix (ECM). These diseases are probably an inevitable aspect of aging, related to the repetitive mechanical stresses to which valves are subjected — 40 million beats per year, with each normal opening and closing requiring substantial valve deformation." — Robbins & Kumar Basic Pathology

Risk factors mirror atherosclerosis: male sex, elevated LDL, hypertension, diabetes, and smoking — all of which promote endothelial injury, lipid deposition, and calcification. — Robbins & Kumar Basic Pathology

---

3. Mitral Regurgitation (MR) — Definition

In Degenerative MR:

• Myxomatous/mitral valve prolapse (MVP): One or both mitral leaflets balloon back ("prolapse") into the left atrium during systole due to myxomatous thickening (thinned fibrosa, expanded mucoid spongiosa), elongated or ruptured chordae → regurgitant jet
• Mitral annular calcification (MAC): Calcific deposits in the mitral annulus restrict normal annular contraction and/or cause leaflet restriction → regurgitation (and occasionally stenosis)
• Fibroelastic deficiency: Age-related reduction in collagen, elastin, and proteoglycans → thin, translucent leaflets with chordal rupture → acute or chronic MR

Degree — Moderate MR:

---

4. Aortic Regurgitation (AR) — Definition

• Intrinsic cusp disease — degenerative fibrocalcific changes that stiffen and retract cusps, preventing normal coaptation
• Aortic root/annular dilation — even structurally normal cusps cannot coapt if the annulus is too wide (age-related aortic root dilation, hypertension)

Degree — Moderate AR:

---

5. Aortic Stenosis (AS) — Definition

"Aortic stenosis (AS) is a narrowing of the aortic valve that can result in chest pain, dyspnea, presyncope or syncope, fatigue, and palpitations." — Kaplan & Sadock's Comprehensive Textbook

In Degenerative (Calcific) AS:

"Calcific aortic degeneration is the most common cause of aortic stenosis... the hallmark is heaped-up calcified masses on the outflow side of the cusps, protruding into the sinuses of Valsalva and mechanically impeding valve opening. Commissural fusion is NOT a typical feature — distinguishing it from rheumatic AS." — Robbins & Kumar Basic Pathology

• Endothelial injury (from mechanical stress, hypertension, lipid deposition) → lipid accumulation → macrophage and T-lymphocyte infiltration → fibrosis → progressive calcification immobilizing leaflets
• Calcific deposits begin at the base of leaflets and extend toward the tips
• The process shares the pathobiology of atherosclerosis — hence the identical risk factor profile

Degree — Moderate AS:

---

Summary Definition Table

---

• Robbins & Kumar Basic Pathology (Robbins Pathology) — Degenerative Valve Disease section (pp. 854–892)
• Braunwald's Heart Disease, 2-Volume Set — Chapters 72, 73, 76
• Kaplan & Sadock's Comprehensive Textbook — Aortic Valve Disease
• Mulholland and Greenfield's Surgery, 7th Ed. — Degenerative Calcific Aortic Stenosis (Table 82.1)
• Fuster and Hurst's The Heart, 15th Ed.